WEBULL

Praxis Precision Medicines (PRAX) Valuation Check After Big Three Year Return And Price To Book Premium

Simply Wall St · 2d ago

Praxis Precision Medicines: Stock Snapshot After Recent Moves

Praxis Precision Medicines (PRAX) has attracted fresh attention after recent trading swings, with the stock showing a 3.3% decline over the past day but a gain over the past month.

See our latest analysis for Praxis Precision Medicines.

Recent moves sit within a much bigger swing, with a 90 day share price return of 410.08% and a very large 3 year total shareholder return. This suggests momentum has been building despite short term pullbacks.

If Praxis’s recent surge has you thinking about the wider sector, this could be a good moment to check out other healthcare stocks that are moving on clinical and pipeline updates.

With Praxis now trading at US$276.92 and sitting at a very large 3 year total return, plus a big gap to the average analyst price target, you have to ask: is there real value left here, or is the market already pricing in future growth?

Price to Book of 20.2x: Is It Justified?

On a P/B of 20.2x and a last close of US$276.92, Praxis Precision Medicines currently trades far above typical book value multiples for its peer group.

P/B compares the share price to the company’s net assets on the balance sheet. It is often used as a reference point for early stage or unprofitable biotechs where earnings are still negative.

According to the data, PRAX is described as expensive on a P/B basis versus both the US Biotechs industry average of 2.7x and a peer group average of 16.8x. That suggests the market is attaching a much richer value to Praxis’s pipeline and future prospects than to the underlying balance sheet, with a premium that stands out even within its own sector.

Relative to the broader industry, the wording is clear: PRAX’s 20.2x P/B is described as expensive versus the 2.7x sector level, and still expensive even against peers at 16.8x. That indicates that the current share price embeds higher expectations than what is typical across comparable biotech names.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 20.2x (OVERVALUED)

However, that premium sits against a US$273.04 million net loss and a clinical pipeline in which trial setbacks or funding pressures could quickly challenge the current pricing story.

Find out about the key risks to this Praxis Precision Medicines narrative.

Another View: What Our DCF Says

While the 20.2x P/B ratio paints PRAX as expensive against the US Biotechs industry average of 2.7x and a peer average of 16.8x, our DCF model points in a very different direction, indicating the shares trade about 92.3% below an estimated fair value of US$3,603.38.

This gap between a rich P/B multiple and an undervalued signal from the SWS DCF model raises a practical question for you as an investor: is the market overconfident about book value or underestimating long term cash flow potential?

Look into how the SWS DCF model arrives at its fair value.

PRAX Discounted Cash Flow as at Jan 2026
PRAX Discounted Cash Flow as at Jan 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Praxis Precision Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 879 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Praxis Precision Medicines Narrative

If this take on PRAX does not quite match your view, or you prefer to lean on your own work, you can build a custom thesis in just a few minutes. To get started, use Do it your way.

A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger watchlist, do not stop at one company. Use the screener to uncover ideas other investors are already hunting for.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.